Contraindications for physostigmine use include the presence of:

- Hypersensitivity to the drug, drug class, or any formulation components

- Pulmonary disease-causing bronchoconstriction of the airways, such as asthma

- Gangrene

- Diabetes mellitus

- Cardiovascular disease

- Gastrointestinal or urogenital tract obstruction

- Angle-closure glaucoma

- Coexisting medications with choline esters and depolarizing neuromuscular blockers or a salicylate/sulfite allergy

- Genitourinary tract obstruction

- Arrhythmia patients

- Neonates

Caution is necessary when administering to patients with bradycardia, vagal tone increase, peptic ulcer disease, gastroesophageal reflux disease, hypotension, hyperthyroidism, and patients with seizure disorders.

Patients with QRS prolongation on EKG or those with a history of overdose with QRS prolonging medications should not receive physostigmine.

Physostigmine is FDA Pregnancy Category C. A study looking at information collected between 2010 and 2012 by the Toxicology Investigators Consortium (ToxIC) Registry of the American College of Medical Toxicology suggested that clinicians used physostigmine in 4% of cases involving pregnant women (N=103).